+

WO2006012577A3 - Derives de la quinazolinone utiles pour la regulation de l'homeostasie du glucose et de prise d'aliments - Google Patents

Derives de la quinazolinone utiles pour la regulation de l'homeostasie du glucose et de prise d'aliments Download PDF

Info

Publication number
WO2006012577A3
WO2006012577A3 PCT/US2005/026192 US2005026192W WO2006012577A3 WO 2006012577 A3 WO2006012577 A3 WO 2006012577A3 US 2005026192 W US2005026192 W US 2005026192W WO 2006012577 A3 WO2006012577 A3 WO 2006012577A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulation
food intake
quinazolinone derivatives
derivatives useful
glucose homeostasis
Prior art date
Application number
PCT/US2005/026192
Other languages
English (en)
Other versions
WO2006012577A2 (fr
Inventor
Joachim Rudolph
Stephen O'connor
Philip Coish
Philip Wickens
Georgiy Bondar
Chih-Yuan Chuang
Philip Ramsden
Derek Lowe
Donald Bierer
Libing Chen
Wenlang Fu
Uday Khire
Xiao-Gao Liu
Andrea Mcclure
Lei Wang
Lin Yi
William Esler
Original Assignee
Bayer Pharmaceuticals Corp
Joachim Rudolph
Stephen O'connor
Philip Coish
Philip Wickens
Georgiy Bondar
Chih-Yuan Chuang
Philip Ramsden
Derek Lowe
Donald Bierer
Libing Chen
Wenlang Fu
Uday Khire
Xiao-Gao Liu
Andrea Mcclure
Lei Wang
Lin Yi
William Esler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Joachim Rudolph, Stephen O'connor, Philip Coish, Philip Wickens, Georgiy Bondar, Chih-Yuan Chuang, Philip Ramsden, Derek Lowe, Donald Bierer, Libing Chen, Wenlang Fu, Uday Khire, Xiao-Gao Liu, Andrea Mcclure, Lei Wang, Lin Yi, William Esler filed Critical Bayer Pharmaceuticals Corp
Publication of WO2006012577A2 publication Critical patent/WO2006012577A2/fr
Publication of WO2006012577A3 publication Critical patent/WO2006012577A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a trait à des dérivés de la quinazolinone, des compositions, et des procédés de traitement du diabète, de l'obésité et autres troubles associés, et de la régulation de la prise d'aliments (par exemple, stimulation et suppression).
PCT/US2005/026192 2004-07-22 2005-07-22 Derives de la quinazolinone utiles pour la regulation de l'homeostasie du glucose et de prise d'aliments WO2006012577A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59080404P 2004-07-22 2004-07-22
US60/590,804 2004-07-22

Publications (2)

Publication Number Publication Date
WO2006012577A2 WO2006012577A2 (fr) 2006-02-02
WO2006012577A3 true WO2006012577A3 (fr) 2006-09-28

Family

ID=35786753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/026192 WO2006012577A2 (fr) 2004-07-22 2005-07-22 Derives de la quinazolinone utiles pour la regulation de l'homeostasie du glucose et de prise d'aliments

Country Status (1)

Country Link
WO (1) WO2006012577A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2584507C (fr) 2004-10-20 2016-04-26 Resverlogix Corp. Flavanoides et isoflavanoides pour la prevention et le traitement de maladies cardio-vasculaires
JP2009525292A (ja) * 2006-01-31 2009-07-09 エフ．ホフマン−ラ ロシュ アーゲー ７ｈ−ピリド［３，４−ｄ］ピリミジン−８−オン、それらの製造及びプロテインキナーゼ阻害剤としての使用
MX2009002686A (es) * 2006-09-11 2009-10-13 Organon Nv Derivados de acetamida de quinazolinona e isoquinolinona.
JP5236664B2 (ja) 2007-02-01 2013-07-17 レスバーロジックス コーポレイション 心血管疾患を予防および治療するための化合物
CN101531638B (zh) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
WO2009143049A1 (fr) 2008-05-19 2009-11-26 Schering Corporation Dérivés hétérocycliques bicycliques et leur utilisation en tant que modulateurs de gpr119
WO2009158404A1 (fr) * 2008-06-26 2009-12-30 Resverlogix Corp. Procédés de préparation de dérivés de quinazolinone
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
FR2938538B1 (fr) * 2008-11-17 2011-08-05 Univ Nice Sophia Antipolis Procede de preparation d'acides et d'esters boroniques en presence de magnesium metallique
JP2012051803A (ja) * 2008-12-25 2012-03-15 Kyorin Pharmaceutical Co Ltd 環状アミノ安息香酸エステル誘導体の製造方法
CA2747417C (fr) 2009-01-08 2017-01-03 Resverlogix Corp. Composes pour la prevention et le traitement de maladies cardiovasculaires
WO2010106436A2 (fr) 2009-03-18 2010-09-23 Resverlogix Corp. Nouveaux agents anti-inflammatoires
ES2706651T3 (es) 2009-04-22 2019-03-29 Resverlogix Corp Nuevos agentes antiinflamatorios
WO2011075699A2 (fr) * 2009-12-18 2011-06-23 Sunovion Pharmaceuticals Inc. Composés pour le traitement des troubles médiés par le récepteur métabotropique 5 du glutamate, et leurs méthodes d'utilisation
GB201004739D0 (en) * 2010-03-22 2010-05-05 Prosidion Ltd Receptor modulators
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2565186A1 (fr) * 2011-09-02 2013-03-06 Hybrigenics S.A. Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine
SI2773354T1 (sl) 2011-11-01 2019-08-30 Resverlogix Corp. Peroralne formulacije s takojšnjim sproščanjem za substituirane kinazolinone
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
CA2895905A1 (fr) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Nouveaux composes heterocycliques en tant qu'inhibiteurs de bromodomaine
GB201313664D0 (en) 2013-07-31 2013-09-11 Univ Cardiff Bcl-3 inhibitors
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
US10675283B2 (en) 2017-03-24 2020-06-09 University Of South Florida Compositions and methods for white to beige adipogenesis
WO2018184115A1 (fr) * 2017-04-06 2018-10-11 London Health Sciences Centre Research Inc. Dérivés de quinazolinone utiles pour l'imagerie
WO2019104324A1 (fr) * 2017-11-27 2019-05-31 The Scripps Research Institute Antagoniste de ghsr1a pour le traitement du syndrome de prader-willi
CN110698392A (zh) * 2019-09-09 2020-01-17 中国农业大学 一种双酰胺类化合物及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033792A1 (fr) * 1997-01-31 1998-08-06 Kyowa Hakko Kogyo Co., Ltd. Derives de la piperidine
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033792A1 (fr) * 1997-01-31 1998-08-06 Kyowa Hakko Kogyo Co., Ltd. Derives de la piperidine
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAKER B.R. ET AL.: "An Antimalarial Alkaloid From Hydrangea. IV. Functional Derivatives of 3-Alkyl-4-Quinazolones", J. ORG. CHEM., vol. 17, 1952, pages 35 - 51 *

Also Published As

Publication number Publication date
WO2006012577A2 (fr) 2006-02-02

Similar Documents

Publication Publication Date Title
WO2006012577A3 (fr) Derives de la quinazolinone utiles pour la regulation de l'homeostasie du glucose et de prise d'aliments
WO2007016538A3 (fr) Preparation et utilisation de derives aminoacides biphenyle pour traiter l'obesite
WO2006044775A3 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
WO2008116139A3 (fr) Composés utiles en tant qu'inhibiteurs des kinases de janus
WO2005119627A3 (fr) Dispositifs personnels de controle de la nutrition
WO2007109354A3 (fr) Conjugués inhibiteur de peptidase-peptide et procédés d'utilisation de ceux-ci
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2006083533A3 (fr) Compositions et methodes d'inhibition de la formation de drusen et methodes de diagnostic ou de traitement de pathologies liees aux drusen
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
WO2008076392A3 (fr) Composés utilisables en tant qu'inhibiteurs de protéines kinases
WO2007041365A3 (fr) Composes organiques
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
WO2005046603A3 (fr) Composes pyridiniques
WO2004100881A3 (fr) Preparation et utilisation de derives d'aryl alkyl acide pour le traitement de l'obesite
WO2007104789A3 (fr) Dérivés d'amyline
WO2006020959A3 (fr) Heterocycles benzo-condenses substitues
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
WO2006113919A3 (fr) Preparation et utilisation de derives de l'acide aryle alkyle dans le traitement de l'obesite
WO2009042922A3 (fr) Conjugués inhibiteurs de peptide/peptidase et leurs procédés de fabrication et d'utilisation
WO2009068246A3 (fr) Procédés de traitement de l'obésité et de troubles métaboliques
WO2007079214A3 (fr) Antagonistes du recepteur de la prokineticine 2
WO2007050793A3 (fr) Methodes et compositions de traitement du syndrome de marfan et de troubles associes
WO2006034154A3 (fr) Sels de 5-azacytidine
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
WO2006116609A8 (fr) Procedes permettant de traiter les maladies des neurones moteurs peripheriques et compositions associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载